Skip to content
DraconiticResearch
Search Sources API
186,625 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BY-NC-NDExperimental and therapeutic medicine

Advances in drug prevention and treatment of radiation-induced lung injury (Review).

  • Shuo Liu1
  • Minting Ma2
  • Chanjun Zhen1
  • Yang Zhao3
  • Yuzhi Song1
  • Qiuying An1
  • Zhiguo Zhou1
  • Wenwen Bai1
  1. 1Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
  2. 2Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
  3. 3Office of Scientific Research, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
Read full textPDFDOICite

Abstract

Radiation-induced lung injury (RILI), including radiation pneumonitis and radiation-induced pulmonary fibrosis, is a common complication during or after radiotherapy for thoracic tumors. This complication severely restricts dose escalation in radiotherapy and delays subsequent antitumor treatment, thereby compromising patient prognosis. Therefore, it is crucial to develop safe and effective drug prevention and treatment strategies to ensure successful implementation of radiotherapy and improve patient prognosis. The present review systematically assesses recent advances in drug prevention and treatment-based approaches for RILI, focusing on the underlying molecular mechanisms and key therapeutic targets at different developmental phases of RILI (oxidative stress, inflammatory response and fibrosis formation). Progress from classical radioprotective agents and anti-inflammatory drugs to novel antifibrotic drugs and cutting-edge exploratory therapies are also comprehensively summarized, with an aim to inform clinical practice and guide future research directions.

Related

  1. Nintedanib in the prevention of radiation-induced lung injury in patients with unresectable stage II-III NSCLC: A protocol for a randomized, multicenter, control group study
    Ai Cui, Anhui Shi, Lei Deng +4
    PLOS OnePeer-reviewedCC BY 4.0Full textMedical imaging & radiologyOncologyPLOS
  2. Herpes Simplex Virus: Molecular Pathogenesis, Type-Specific Disease Burden, and Advances in Prevention and Treatment.
    Chenhao Jiang, Jianhui Nie, Li Zhang
    VirusesPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  3. Pediatric MASLD in the precision medicine era: advances in diagnosis, prevention, and treatment
    Anastasia Ntikoudi, Anastasia Papachristou, Eugenia Vlachou
    Frontiers in medicinePeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCEurope PMCPMC
  4. Advances in the Diagnosis and Treatment of Pediatric Sepsis-Associated Acute Kidney Injury.
    Junhan Chai, Zuoyu Wen, Yanna Guo +7
    Journal of inflammation researchPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  5. A spatiotemporal atlas of radiation-induced brain injury reveals dysfunction of the blood-CSF barrier
    Cheng Quan, Yan Gao, Xinyi Liu +18
    Cell Reports MedicinePeer-reviewedCC BY-NC-ND 4.0Full textNeurologyPMC

Cite

BibTeXRIS
BibTeX
@article{liu2026advances,
  title = {{Advances in drug prevention and treatment of radiation-induced lung injury (Review).}},
  author = {Shuo Liu and Minting Ma and Chanjun Zhen and Yang Zhao and Yuzhi Song and Qiuying An and Zhiguo Zhou and Wenwen Bai},
  journal = {Experimental and therapeutic medicine},
  year = {2026},
  month = sep,
  doi = {10.3892/etm.2026.13318},
  url = {https://europepmc.org/article/MED/42924062},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Advances in drug prevention and treatment of radiation-induced lung injury (Review).
AU  - Shuo Liu
AU  - Minting Ma
AU  - Chanjun Zhen
AU  - Yang Zhao
AU  - Yuzhi Song
AU  - Qiuying An
AU  - Zhiguo Zhou
AU  - Wenwen Bai
PY  - 2026
DA  - 2026/09/29
JO  - Experimental and therapeutic medicine
DO  - 10.3892/etm.2026.13318
UR  - https://europepmc.org/article/MED/42924062
AB  - Radiation-induced lung injury (RILI), including radiation pneumonitis and radiation-induced pulmonary fibrosis, is a common complication during or after radiotherapy for thoracic tumors. This complication severely restricts dose escalation in radiotherapy and delays subsequent antitumor treatment, thereby compromising patient prognosis. Therefore, it is crucial to develop safe and effective drug prevention and treatment strategies to ensure successful implementation of radiotherapy and improve patient prognosis. The present review systematically assesses recent advances in drug prevention and treatment-based approaches for RILI, focusing on the underlying molecular mechanisms and key therapeutic targets at different developmental phases of RILI (oxidative stress, inflammatory response and fibrosis formation). Progress from classical radioprotective agents and anti-inflammatory drugs to novel antifibrotic drugs and cutting-edge exploratory therapies are also comprehensively summarized, with an aim to inform clinical practice and guide future research directions.
SN  - 1792-0981
SN  - 1792-1015
ER  -